<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136119">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01840280</url>
  </required_header>
  <id_info>
    <org_study_id>ONKOIRI01</org_study_id>
    <nct_id>NCT01840280</nct_id>
  </id_info>
  <brief_title>A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer</brief_title>
  <official_title>Open, Multicenter Observational Study of Irinotecan Utilized in Mono- or Combination Therapy for the Treatment of Advanced Colorectal Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Onkovis GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AKP Freiburg GmbH (Clinical Research Organization)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Onkovis GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this observational study with Irinotecan onkovis is to determine the
      number of treatment cycles and the quantity of Irinotecan onkovis needed for this purpose
      under the special circumstances of ambulant chemotherapy.

      Onkovis aims to contribute to an economical utilization of the chemotherapeutics. This
      includes provision of appropriate packaging sizes to decrease the excess quantity to be
      discarded, and thus also follows this objective.

      Secondary objective is the assessment of the side effects of Irinotecan onkovis. To this
      end, data regarding co-medication and adverse events are also collected.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The Quantity of Irinotecan onkovis needed per treatment cycle</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine the quantity of Irinotecan onkovis needed pro treatment cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events during and after treatment</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number and kind of adverse events during and after the intra-venous application of Irinotecan will be assessed and documented.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>Carcinoma, Irinotecan onkovis (Irinotecan)</arm_group_label>
    <description>Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated in practices, clinics, hospitals
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for Irinotecan according to the SmPC and treating physician

        Exclusion Criteria:

          -  according to the Irinotecan SmPC
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Klaus-Ulrich Seiler, PD Dr. med.</last_name>
    <phone>+49(0)761479400</phone>
    <email>info@akp-freiburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Elstra</city>
        <zip>01920</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Leipzig</city>
        <zip>04179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Naunhof</city>
        <zip>04683</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Neustadt/Sachsen</city>
        <zip>01844</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Practice</name>
      <address>
        <city>Werdau</city>
        <zip>08412</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>April 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carcinoma</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>ambulant chemotherapy</keyword>
  <keyword>treatment cycles</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Irinotecan onkovis</keyword>
  <keyword>Quantity of Irinotecan</keyword>
  <keyword>Packaging Sizes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
